🇺🇸 FDA
Patent

US 8921050

Methods of diagnosing renal cell carcinoma

granted A61KA61K2039/585A61K2239/56

Quick answer

US patent 8921050 (Methods of diagnosing renal cell carcinoma) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K2039/585, A61K2239/56, A61K35/12, A61K35/17